Latest news with #SiemensHealthineers'
Mid East Info
25-03-2025
- Health
- Mid East Info
Innovation Capacity Building Program Concluded Successfully by Siemens Healthineers in Saudi Arabia - Middle East Business News and Information
In addition to showcasing its commitment to capacity building and innovation, Siemens Healthineers demonstrated its innovative approach to healthcare transformation, leveraging global expertise and partnerships to drive sustainable growth in Saudi Arabia. The Innovation Capacity Building Program, conducted by Siemens Healthineers through its Regional Headquarters (RHQ) in Saudi Arabia, has successfully concluded. Held from February 5-20, 2025, the program aimed to strengthen local expertise and foster strategic collaborations with universities, hospitals, startups, and key stakeholders such as Monshaat. Bringing together 40 participants from diverse backgrounds including doctors, engineers, healthcare professionals, researchers, and students the comprehensive two-week initiative facilitated cross-disciplinary synergies, enabling participants to identify critical healthcare gaps and develop innovative solutions to address them. This program highlights Siemens Healthineers' commitment to enhancing healthcare capabilities within the Kingdom. With the increasing urge to overcome pressing healthcare challenges, the program put the spotlight on three main project workstreams: Disease Pathways, Healthcare Systems of the Future and Medical curriculum of the Future. As part of these workstreams, participants utilized the Innovation Methodologies to develop data-driven, patient-centric solutions optimizing the healthcare delivery and improving outcomes. Dr. Abdulaziz Alhomod, Head of Radiology at SEHA Virtual Hospital, Ministry of Health, expressed his pride in the program's success, stating: 'Innovation is the cornerstone of transformative healthcare. It was a great experience to join Siemens Healthineers Innovation Capacity Building Program, which reaffirms the power of innovation and collaboration in shaping future care delivery. This experience fuels my commitment to continuous engagement with Siemens Healthineers to build local innovation, entrepreneurship, and commercialization expertise, identify and address the key healthcare challenges, and improve cross-institutional collaborations.' The program was concluded with the Outcome Exhibition on February 20, 2025, at Monshaat Startup Hub in Riyadh. Monshaat, Saudi Arabia's Small and Medium Enterprises General Authority, plays a key role in fostering entrepreneurship and innovation, making it an ideal partner for this program. At this edition of the program, Siemens Healthineers led the positive change in the healthcare digital world by providing an overview of its comprehensive solutions portfolio, including innovation and scientific partnerships, as well as education and capacity-building initiatives. About Siemens Healthineers: Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2023, which ended on September 30, 2023, Siemens Healthineers had approximately 71,000 employees worldwide and generated revenue of around €21.7 billion.
Zawya
17-02-2025
- Health
- Zawya
Siemens Healthineers introduces cutting-edge molecular imaging technology to transform Egypt's healthcare sector
Siemens Healthineers reaffirms its commitment to enhancing healthcare services and accessibility in Egypt Cairo, Egypt – Siemens Healthineers, a global leader in medical technology, has introduced its latest molecular imaging solutions to the Egyptian market for the first time. The launch includes two groundbreaking products, including the Biograph Trinion PET/CT and the Symbia SPECT/CT. These cutting-edge imaging systems deliver advanced diagnostic capabilities, reinforcing Siemens Healthineers' ongoing commitment to advancing the healthcare sector and providing high-quality, accessible, and sustainable healthcare services for all. During a prestigious event attended by leading healthcare experts and radiology professionals, Siemens Healthineers Egypt unveiled its latest products. The event facilitated an exchange of expertise and insights on the latest advancements in medical imaging, highlighting the significance of these two devices in enhancing healthcare quality and enabling more accurate diagnoses. This underscores Siemens Healthineers' commitment to advancing Egypt's healthcare sector and its dedication to delivering cutting-edge technologies that improve patient care. Following successful international introductions, these solutions are now available in the Egyptian market, where they bring unprecedented accuracy and clarity in medical imaging. The Biograph Trinion PET/CT features an innovative design that enhances tumor imaging, facilitates earlier disease detection, and supports more informed treatment decisions. Meanwhile, the Symbia SPECT/CT redefines imaging standards with its high speed and accuracy in CT imaging, allowing for more precise disease detection and streamlined workflows for clinicians. With a user-friendly interface, smart workflow, and specialized tools, these devices offer flexibility to meet diverse medical needs, marking a significant advancement in Egypt's healthcare landscape. Commenting on the launch, Amro Kandil, managing director of Siemens Healthineers Egypt, stated: 'Siemens Healthineers is dedicated to delivering cutting-edge medical solutions that enhance healthcare services in Egypt. These new imaging systems will enable faster, more accurate diagnoses, supporting healthcare providers in delivering better patient care.' 'Siemens Healthineers is committed to providing comprehensive and sustainable healthcare solutions for all Egyptians. Our primary goal is to deliver innovative technologies that enhance healthcare services across the country.' Kandil also added, 'With these new imaging systems, diseases can be diagnosed faster and with greater accuracy, enabling healthcare providers to complete necessary diagnostic procedures efficiently. This reflects our dedication to equipping Egypt's healthcare institutions with the latest medical solutions.' Ahmed Hafez, Head of Diagnostic Imaging & Advanced Therapy at Siemens Healthineers Egypt, added: 'We are proud to launch these two devices for the first time in the Egyptian market. This is a significant step towards providing more advanced healthcare services in Egypt. The devices feature advanced imaging technologies, such as high-speed, low-dose CT scanning, delivering detailed images, and automatic motion correction with SPECT technology, which enhances clarity. Hafez also added: 'Siemens Healthineers continues to strengthen its position as a leading medical technology company, supporting the Egyptian healthcare sector and improving access to high-quality healthcare solutions.' With a diverse portfolio of innovative solutions, including imaging, diagnosis, and advanced treatments, Siemens Healthineers remains dedicated to supporting the advancement of healthcare in Egypt. The company is also committed to enhancing the efficiency of medical services and empowering healthcare institutions to provide more accurate and faster care through advanced and sustainable technological solutions Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on September 30, 2024, Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around €22.4 billion.
Yahoo
30-01-2025
- Business
- Yahoo
Is Siemens Healthineers AG (ETR:SHL) Trading At A 44% Discount?
Siemens Healthineers' estimated fair value is €97.80 based on 2 Stage Free Cash Flow to Equity Siemens Healthineers is estimated to be 44% undervalued based on current share price of €54.58 Analyst price target for SHL is €60.04 which is 39% below our fair value estimate Does the January share price for Siemens Healthineers AG (ETR:SHL) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking the expected future cash flows and discounting them to today's value. This will be done using the Discounted Cash Flow (DCF) model. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine. We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model. View our latest analysis for Siemens Healthineers We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value: 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Levered FCF (€, Millions) €2.77b €2.91b €3.41b €4.18b €4.57b €4.85b €5.07b €5.25b €5.39b €5.50b Growth Rate Estimate Source Analyst x7 Analyst x7 Analyst x3 Analyst x1 Analyst x1 Est @ 6.06% Est @ 4.53% Est @ 3.46% Est @ 2.71% Est @ 2.18% Present Value (€, Millions) Discounted @ 5.3% €2.6k €2.6k €2.9k €3.4k €3.5k €3.6k €3.5k €3.5k €3.4k €3.3k ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = €32b The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 1.0%. We discount the terminal cash flows to today's value at a cost of equity of 5.3%. Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = €5.5b× (1 + 1.0%) ÷ (5.3%– 1.0%) = €129b Present Value of Terminal Value (PVTV)= TV / (1 + r)10= €129b÷ ( 1 + 5.3%)10= €77b The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is €109b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of €54.6, the company appears quite good value at a 44% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent. The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Siemens Healthineers as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 5.3%, which is based on a levered beta of 1.047. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. Strength Earnings growth over the past year exceeded the industry. Debt is well covered by earnings. Dividends are covered by earnings and cash flows. Weakness Dividend is low compared to the top 25% of dividend payers in the Medical Equipment market. Opportunity Annual revenue is forecast to grow faster than the German market. Good value based on P/E ratio and estimated fair value. Threat Debt is not well covered by operating cash flow. Annual earnings are forecast to grow slower than the German market. Valuation is only one side of the coin in terms of building your investment thesis, and it is only one of many factors that you need to assess for a company. DCF models are not the be-all and end-all of investment valuation. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. Can we work out why the company is trading at a discount to intrinsic value? For Siemens Healthineers, there are three important items you should consider: Risks: Case in point, we've spotted 1 warning sign for Siemens Healthineers you should be aware of. Future Earnings: How does SHL's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered! PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the XTRA every day. If you want to find the calculation for other stocks just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hi Dubai
27-01-2025
- Health
- Hi Dubai
Siemens Healthineers Unveils Groundbreaking Medical Imaging Innovations at Arab Health 2025
Siemens Healthineers, a global leader in medical technology, is set to revolutionize medical imaging with the debut of its cutting-edge technologies at Arab Health 2025, held from January 27 to 30 at the Dubai World Trade Centre. Highlighting its commitment to advancing healthcare sustainably, the company introduces the NAEOTOM® Alpha class, powered by Quantum Technology and AI, and the MAGNETOM Flow platform, a next-generation 1.5T MRI solution. The NAEOTOM® Alpha class, comprising three photon-counting CT systems, delivers unprecedented anatomical precision with Quantum HD resolution up to 0.2 mm and Quantum Spectral imaging for functional evaluations. Vivek Kanade, Managing Director for the Middle East and Africa, remarked, 'At Siemens Healthineers, innovation drives everything we do. Our solutions empower healthcare professionals to make precise, timely decisions, transforming patient care worldwide.' The MAGNETOM Flow platform enhances sustainability with low power consumption, shorter examination times, and improved patient comfort, ensuring efficient and cooperative MRI experiences. Visitors can also explore advanced solutions such as the ACUSON Sequoia 3.5 for AI-driven ultrasound, the Biograph Trinion PET/CT for exceptional diagnostic accuracy, and cutting-edge X-ray platforms like the LUMINOS and MAMMOMAT Siemens Healthineers' booth (S1.C10) offers an immersive, patient-centric journey through clinical pathways in oncology, neurology, and cardiology. The exhibit showcases innovations in diagnostic imaging and cancer therapy while underscoring collaborations with healthcare providers in the Middle East to advance equity, access, and sustainability. Guided by its purpose — "We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably" — Siemens Healthineers invites visitors to experience the future of care delivery at Arab Health 2025. News Source: Gambit Communications
Zawya
27-01-2025
- Health
- Zawya
Siemens Healthineers unveil revolutionary innovations in line with ambitious sustainability goals at Arab Health 2025
Siemens Healthineers to launch their latest photon-counting CT scanner and virtually helium-free Magnetic Resonance Imaging platform Siemens Healthineers, the global leader in medical technology, is set to redefine medical imaging with the launch of a transformative computed tomography (CT) scanner powered by Quantum Technology and AI at Arab Health 2025 (January 27-30, Dubai World Trade Centre). The NAEOTOM® Alpha class highlights Siemens Healthineers' commitment to pioneering breakthroughs in healthcare for everyone, everywhere. Sustainably. Vivek Kanade, Managing Director, Siemens Healthineers, Middle East and Africa said: 'At Siemens Healthineers, innovation is in our DNA and at the core of everything we do. We are continuously pushing the boundaries of medical technology to make diagnoses and treatments more accurate and timelier. From advanced imaging systems, human-centered laboratory designs and intelligent cancer care to AI-driven diagnostic tools, we are creating solutions that enable healthcare professionals to make quicker, more precise decisions. These innovations not only improve patient outcomes, but also help make healthcare more accessible, equitable, and faster, ultimately transforming the way care is delivered worldwide. At Arab Health 2025, we will take visitors on a patient-centric journey of how we believe the future of care delivery will look like' Siemens Healthineers has made an unstoppable commitment to transform medical imaging with photon-counting CT, now presenting the NAEOTOM® Alpha class, three photon-counting CT systems that can support diagnostic results and processes in many clinical scenarios. Proven Quantum Technology enables profound clinical impact, supported by AI-powered productivity solutions. The NAEOTOM® Alpha class delivers precise anatomical details with Quantum HD resolution with up to 0.2 mm, and Quantum Spectral imaging in every scan enables precise functional evaluation. Address limitations of conventional CT and experience the profound clinical impact of photon-counting CT. Making its regional debut, Siemens Healthineers also introduces at Arab Health 2025 the MAGNETOM Flow. Platform, a next-generation 1.5T Magnetic Resonance Imaging (MRI) solution. Designed for sustainability by combining an independent magnet and low power consumption, enhancing patient comfort, contributing to greater workflow efficiency and shorter examination times. Patient well-being is pivotal to MRI examinations, promoting cooperation, more precise results and reducing the need for repeat examinations. Adopting a patient-centric perspective, the Siemens Healthineers booth at Arab Health 2025 transforms into an immersive journey, mirroring clinical pathways in oncology, neurology, and cardiology that are navigated by healthcare providers and patients alike. It showcases how innovations in diagnostic imaging, laboratory diagnostics, and cancer therapy intersect to address the world's most pressing healthcare challenges, including cancer, stroke, and cardiovascular diseases. Guided by its purpose — "We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably" – Siemens Healthineers' booth shows how it is addressing global healthcare challenges while advancing access, equity, and sustainability in the region. The booth will also take visitors on a digital journey through Siemens Healthineers' collaborations with public and private healthcare providers in the Middle East, underscoring their commitment to future-proofing local healthcare systems through digital transformation, automation, and value-driven solutions. Additional highlights at Arab Health 2025 Visitors at the Siemens Healthineers booth will also receive hands-on experiences with solutions across key fields including: Ultrasound: The ACUSON Sequoia 3.5, the industry's first abdominal scanning system with advanced AI, enables real-time organ labeling and measurements, streamlining workflows and delivering unparalleled precision. Molecular Imaging: The Biograph Trinion PET/CT (positron emission tomography / computed tomography) scanner offers ultra-fast time-of-flight performance and exceptional small lesion detectability, ensuring accurate diagnostics with reduced radiation doses. X-Ray Imaging: The LUMINOS fluoroscopy platform and the MAMMOMAT mammography system introduce new dimensions in multifunctionality and patient-centric imaging. Join Siemens Healthineers at Booth S1.C10 from January 27-30, at Arab Health 2025 to experience these innovations firsthand and glimpse the future of healthcare. -Ends- About Siemens Healthineers Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on September 30, 2024, Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around €22.4 billion. Further information is available at For more information, please contact: Gambit Communications Tony Sidgwick Account Director tony@
